Wegovy

Weight Management

Wegovy is used to help adults and children aged 12 years and older who have obesity or are overweight and have weight-related medical problems lose weight and keep it off. It is intended for use alongside a reduced-calorie diet and increased physical activity.

For adults, healthcare providers typically prescribe this medication if the patient has:

• A body mass index (BMI) of 30 or greater (obesity).
• A BMI of 27 or greater (overweight) and at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

For children 12 years and older, it is used for those with an initial BMI at or above the 95th percentile for their age and sex.

Cardiovascular Risk Reduction

Wegovy is also used in adults with known heart disease who are either overweight or have obesity. In these patients, it is prescribed to help reduce the risk of major cardiovascular events, including:

• Heart attack
• Stroke
• Death related to heart or blood vessel problems

Mimicking Natural Hormones

Wegovy belongs to a class of drugs known as GLP-1 receptor agonists. It works by acting like a hormone called glucagon-like peptide-1 (GLP-1) that the body naturally produces in the intestines after a meal.

Brain and Appetite

The medication interacts with the parts of the brain that regulate hunger and food intake. By mimicking the GLP-1 hormone, it signals to the brain that the body is full. This helps to:

• Decrease appetite: You may feel less hungry throughout the day.
• Increase satiety: You may feel satisfied with smaller portions of food.

Slowing Digestion

Wegovy also slows down the rate at which the stomach empties its contents into the small intestine. This process, called delayed gastric emptying, keeps food in the stomach longer, which contributes to a prolonged feeling of fullness after eating.

Insulin and Blood Sugar

In addition to its effects on appetite, the medication helps the pancreas release the right amount of insulin when blood sugar levels are high. It also reduces the amount of sugar the liver produces. While these functions are primary for treating diabetes, they are part of how the active ingredient, semaglutide, functions within the body.

Common Side Effects

The most frequent side effects of Wegovy involve the digestive system. These symptoms are often most noticeable when first starting the medication or when increasing the dose. Common side effects include:

• Nausea and vomiting
• Diarrhea or constipation
• Stomach-area pain
• Feeling bloated or gassy
• Heartburn
• Headache
• Fatigue
• Dizziness

Serious Side Effects

Wegovy may cause serious side effects that require immediate medical attention. Contact a healthcare provider right away if you experience:

• Pancreatitis: Severe pain in the stomach area that may move to the back.
• Gallbladder problems: Symptoms such as pain in the upper right stomach, fever, or yellowing of the skin and eyes.
• Kidney problems: Signs of dehydration or changes in urination.
• Serious allergic reactions: Swelling of the face, tongue, or throat, or difficulty breathing.
• Increased heart rate: A racing or pounding heart while resting.
• Vision changes: New or worsening vision issues.
• Depression or suicidal thoughts: Any sudden changes in mood, behaviors, or thoughts.

Thyroid Tumor Risk

In animal studies, semaglutide caused thyroid C-cell tumors. It is unknown if this medication causes these tumors in humans. Wegovy should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or by those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis

Inflammation of the pancreas (pancreatitis) has been reported in clinical trials. Symptoms include severe pain in the upper stomach area that may spread to the back, with or without vomiting. The medication should be discontinued if pancreatitis is suspected.

Gallbladder Problems

Wegovy may cause gallbladder issues, including gallstones or inflammation of the gallbladder. Symptoms can include pain in the upper right abdomen, fever, and yellowing of the skin or eyes (jaundice).

Kidney Injury

Severe gastrointestinal side effects, such as nausea, vomiting, and diarrhea, can lead to dehydration. This dehydration may cause or worsen kidney problems, including acute kidney injury. Monitoring kidney function is important for those experiencing severe stomach issues.

Low Blood Sugar

There is an increased risk of low blood sugar (hypoglycemia) when Wegovy is used alongside other medications for diabetes, such as insulin or sulfonylureas. Blood sugar levels may need to be monitored more frequently when starting or changing doses.

Vision Changes

In patients with type 2 diabetes, rapid improvement in blood sugar control may lead to a temporary worsening of diabetic retinopathy, which is damage to the blood vessels in the eye.

Mental Health and Heart Rate

Monitoring for new or worsening depression, suicidal thoughts, or unusual changes in mood is recommended. Additionally, Wegovy may increase resting heart rate, which should be monitored periodically.

Pregnancy

Wegovy should not be used during pregnancy. Losing weight while pregnant can potentially harm an unborn baby, even if the person is overweight. If you become pregnant while using this medication, you should stop taking it immediately and contact your healthcare provider.

Because Wegovy stays in the body for several weeks after the last dose, it is recommended to stop using the medication at least two months before planning to become pregnant. Animal studies have shown that semaglutide may cause fetal harm, including birth defects and low birth weight, though human data is limited.

Breastfeeding

It is currently unknown whether Wegovy passes into human breast milk or if it could affect a nursing infant. Because of the potential for serious adverse reactions in a breastfed child, you should consult with your doctor to decide whether to stop breastfeeding or stop the medication.

Available Forms

Wegovy is supplied as a clear, colorless solution for subcutaneous injection. It is packaged in single-dose, prefilled pens designed for self-administration.

The medication is intended for injection into the fat layer just under the skin, typically in the stomach area, thigh, or upper arm. Each pen is designed to deliver a single dose and should be discarded after use.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved Wegovy for chronic weight management in adults with obesity or those who are overweight and have at least one weight-related condition, such as high blood pressure or type 2 diabetes. It is also approved for children aged 12 and older who meet specific weight criteria. The medication is intended to be used alongside a reduced-calorie diet and increased physical activity.

In 2024, the FDA expanded the approved use of Wegovy to include reducing the risk of major adverse cardiovascular events, such as heart attack, stroke, or cardiovascular death. This indication applies to adults with established cardiovascular disease who also have obesity or are overweight.

Boxed Warning

Wegovy carries a boxed warning regarding the potential risk of thyroid C-cell tumors. This warning is based on findings from animal studies where semaglutide caused thyroid tumors. It is currently unknown if Wegovy causes these tumors in humans. Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are advised not to use this medication.

Regulatory Oversight

The FDA monitors the safety and promotion of Wegovy. The agency has issued warning letters to the manufacturer regarding promotional materials that were found to be misleading. These letters noted that certain advertisements failed to communicate important risk information or made claims about the drug's benefits that were not adequately supported.

How Wegovy Supports Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. This medication mimics a hormone naturally produced in the body that signals the brain when you are full. By activating these receptors, Wegovy helps reduce hunger, increase feelings of fullness, and slow the rate at which the stomach empties.

Eligibility Criteria

This medication is intended for long-term weight management rather than short-term or cosmetic use. It is typically prescribed for:

• Adults with a body mass index (BMI) of 30 or higher (obesity).
• Adults with a BMI of 27 or higher (overweight) who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
• Pediatric patients aged 12 and older with an initial BMI at or above the 95th percentile for their age and sex.

Treatment Approach

Wegovy is administered as a once-weekly subcutaneous injection. For the medication to be effective, it must be used as part of a comprehensive weight management plan that includes:

• A reduced-calorie diet.
• Increased physical activity.
• Ongoing medical supervision.

Healthcare providers usually start patients on a low dose and gradually increase it over several months to help the body adjust and minimize potential side effects. While Wegovy contains the same active ingredient as Ozempic, it is specifically FDA-approved for weight loss at higher maintenance doses.